ELUTIA INC.

Develops drug-eluting biologics to reduce complications from medical implants.

ELUT | NDAQ

Overview

Corporate Details

ISIN(s):: US05479K1060
LEI:
Country:: United States of America
Address:: 12510 PROSPERITY DRIVE, 20904 SILVER SPRING
Website:: https://elutia.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Elutia Inc. is a commercial-stage company that develops and commercializes drug-eluting biologic products to improve compatibility between medical devices and patients. The company's proprietary drug-eluting biomaterial platforms combine natural biologic materials with extended-release antibiotics to address post-surgical complications from implant failures. Its key offerings include CanGaroo, an acellular device envelope for implantable electronics like pacemakers and neurostimulators, and SimpliDerm, a human acellular dermal matrix for soft tissue reconstruction. These products are designed to mitigate fibrotic responses, ensure implant stability, and support wound healing. Formerly known as Aziyo Biologics, the company rebranded to Elutia to reflect its strategic focus on drug-eluting biomatrices.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ELUTIA INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ELUTIA INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ELUTIA INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Coherus Oncology, Inc. Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.	United States of America	CHRS
COLLEGIUM PHARMACEUTICAL, INC Develops and commercializes abuse-deterrent medications for responsible chronic pain management.	United States of America	COLL
CollPlant Biotechnologies Ltd Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.	United States of America	CLGN
Compass Therapeutics, Inc. A clinical-stage oncology firm developing antibody therapies that engage the immune system.	United States of America	CMPX
Compugen Ltd. Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.	Israel	CGEN
COMPUGEN LTD AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.	United States of America	CGEN
Connect Biopharma Holdings Ltd Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.	United States of America	CNTB
Context Therapeutics Inc. Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.	United States of America	CNTX
Contineum Therapeutics, Inc. Develops oral small molecule therapies for neurological, inflammatory, and fibrotic diseases.	United States of America	CTNM
CORCEPT THERAPEUTICS INC Develops and commercializes cortisol-modulating drugs for severe disorders like Cushing's syndrome.	United States of America	CORT